Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH…
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product…
NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a…
PGN-EDO53 NHP Exon Skipping, PGN-EDO45 and PGN-EDO44 Exon Skipping in Wild-Type Human Myoblasts High levels…
-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal…
FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation…
Completed enrollment in the Phase 1 study with novel, broad-spectrum antiviral PB2 candidate CC-42344 for…
Largest study to date to characterize natural history of rare retinal diseases RESEARCH TRIANGLE PARK,…
Seeking guidance from FDA to proceed towards a Phase 3 clinical study of KETARX™ (ketamine)…
– Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical…
WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical…
Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients…
SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose”) (NASDAQ:…
Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The…
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints…
WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology…
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with…
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) — NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES…
Tolerability of MSP-1014 May Be Superior to Psilocybin TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) —…
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”…